Di Zhao, Ph.D.
Areas of Research
- Prostate Cancer Research
- Targeted Therapy Research
Dr. Zhao’s laboratory in the Experimental Radiation Oncology (ERO) department is interested in the functional genomics of prostate cancers with two primary directives: (1) understanding how oncogenic signaling pathways and tumor microenvironment regulate cancer development and metastasis, and (2) searching for biomarkers and context-specific therapeutic targets for personalized cancer medicine.
Li H, Wang Y, Lin K, Venkadakrishnan VB, Bakht M, Shi W, Meng C, Zhang J, Tremble K, Liang X, Song JH, Feng X, Van V, Deng P, Burks JK, Aparicio A, Keyomarsi K, Chen J, Lu Y, Beltran H, Zhao D. CHD1 promotes sensitivity to Aurora kinase inhibitors by suppressing interaction of AURKA with its coactivator TPX2. Cancer Res. 2022 Jun 30:can.22.0631. doi: 10.1158/0008-5472.CAN-22-0631. Epub ahead of print. PMID: 35771632.
NIH/NCI Pathway to Independence Award (K99/R00)
CPRIT Recruitment of First-Time Tenure-Track Faculty Award
Prostate Cancer Foundation Young Investigator Award
The University of Texas UT System Rising STARs Award
The University of Texas MD Anderson Cancer Center Prostate Cancer SPORE CEP Award